Search clinical trials for: PF-05190457

Total 1295 results

Ablynx

Completed

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects (FIH)

Healthy

United States
Pfizer

Terminated

A Study of PF-04217903 in Patients With Advanced Cancer

Neoplasms

United States
Pfizer

Completed

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

Neoplasms

Korea, Republic of, Australia, United States
Pfizer

Completed

A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated

Healthy

Belgium
Pfizer

Completed

A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers

Pain

Belgium
Pfizer

Completed

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

Neoplasms

Japan
Pfizer

Terminated

Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers

Healthy Volunteers

Singapore
Pfizer

Completed

A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Diabetes Mellitus, Type 2

Belgium
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Active, not recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
Pfizer

Active, not recruiting

PF-07284892 in Participants With Advanced Solid Tumors

Solid Tumor

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous

United States, Spain, Taiwan, Canada, Greece
Pfizer

Recruiting

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Healthy

United States, Belgium
National Institute of Mental Health (NIMH)

Recruiting

[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET

Depression

United States
Pfizer

Recruiting

Lorlatinib Continuation Study

NSCLC | Non-Small-Cell Lung Cancer

Spain, Taiwan, France, China, Singapore, Japan, United States
Pfizer

Active, not recruiting

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Carcinoma, Non-Small-Cell Lung

China
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
Pfizer

Completed

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

Atopic Dermatitis

United States
Yale University

Completed

Translational Neuroscience Optimization of GlyT1 Inhibitor (NCATS)

Cognitive Impairments Associated With Schizophrenia

United States
Pfizer

Completed

Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants

Healthy

Belgium
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee

Osteoarthritis, Knee

Korea, Republic of, United States
Pfizer

Completed

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

Healthy

United States
Pfizer

Completed

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Chile, Czechia
Pfizer

Completed

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Biogen
Yale University

Completed

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Healthy Volunteer

United States
Pfizer

No longer available

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

United States
Pfizer

Withdrawn

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

Tourette's Syndrome

United States
Pfizer

Completed

Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.

Female Sexual Dysfunction

Norway, Denmark, Sweden
Pfizer
Alzheimer's Disease Cooperative Study (ADCS)

Completed

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Pfizer

Terminated

Single Dose Study of PF-06815345 in Healthy Subjects

Hypercholesterolemia

Belgium
Pfizer

Completed

Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

Healthy

United States
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Schizophrenia

United States
Pfizer

Completed

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

Huntington's Disease

France
Pfizer

Completed

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Huntington's Disease

United States, Germany, United Kingdom, Canada, Poland
Pfizer

Completed

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

Healthy Volunteers

United States
Pfizer

Completed

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Pfizer

Terminated

An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom
Pfizer

Terminated

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Pfizer

Completed

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

Healthy

United States
Seoul National University Hospital
Pfizer

Completed

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (PF299804-AGC)

Advanced Gastric Cancer | HER2

Korea, Republic of
Pfizer

Completed

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

Parkinson's Disease

United States
Pfizer

Terminated

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

Healthy Elderly

United States
Pfizer

Completed

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

Healthy

United States
Pfizer

Completed

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Narcolepsy | Excessive Daytime Sleepiness

United States
Pfizer

Completed

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

Hepatitis C

Belgium, Germany, United Kingdom

3

Subscribe